NCT02969252已完成1 期
Pharmacokinetics and Safety Study of Rifamycin SV-MMX® 600 mg Tablets After Single and Multiple t.i.d. Doses in Healthy Male and Female Volunteers. Single and Multiple Dose, Open Label, Pharmacokinetics and Safety Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
- 主要终点
- Cmax
研究概览
简要总结
The objective of the study was to evaluate the pharmacokinetics and the safety of rifamycin SV after single and multiple doses of Rifamycin SV-MMX® 600 mg tablets administered to male and female healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Informed consent: signed written informed consent before inclusion in the study
- •Sex and Age: men and women, 18-55 year old inclusive
- •Body Mass Index: 18.5-30 kgm2 inclusive
- •Vital signs: systolic blood pressure 100-139 mmHg, diastolic blood pressure 50-89 mmHg, heart rate 50-90 bpm, measured after 5 min at rest in the sitting position
- •Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the investigator and to comply with the requirements of the entire study
- •Fertility (women only): women of non-child-bearing potential or in post-menopausal status for at least 1 year.
- •For all female subjects, pregnancy test result had to be negative at screening and Day -1
排除标准
- •ECG 12-leads (supine position): clinically significant abnormalities
- •Physical findings: clinically significant abnormal physical findings which could interfere with the objectives of the study
- •Laboratory analyses: clinically significant abnormal laboratory values indicative of physical illness
- •Allergy: ascertained or presumptive hypersensitivity to the active principle and/or formulations' ingredients; history of anaphylaxis to drugs or allergic reactions in general, which the investigator considered could affect the outcome of the study
- •Diseases: significant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases that could interfere with the aim of the study
- •Medications: medications, including over the counter medications and herbal remedies, for 2 weeks before the start of the study
- •Investigative drug studies: participation in the evaluation of any investigational product for 3 months before this study. The 3-month interval was calculated as the time between the first calendar day of the month that follows the last visit of the previous study and the first day of the present study
- •Blood donation: blood donations for 3 months before this study
- •Drug, alcohol, caffeine, tobacco: history of drug, alcohol (more than 1 drink a day for females and more than 2 drinks a day for males, defined according to the USDA Dietary Guidelines 2010), caffeine (more than 5 cups coffee/tea/day) or tobacco abuse (10 cigarettes a day)
- •Abuse drug test: positive result at the drug test at screening or Day-1
- •Alcohol test: positive alcohol breath test at Day -1
- •Diet: abnormal diets (less than1600 or more than 3500 kcal/day) or substantial changes in eating habits in the 4 weeks before this study; vegetarians
- •Pregnancy (females only): positive or missing pregnancy test at screening or Day -1, pregnant or lactating women
研究组 & 干预措施
Open label
Other
Single and multiple dose, open label, pharmacokinetics and safety study
干预措施: Rifamycin SV-MMX® 600 (Drug)
结局指标
主要结局
Cmax
时间窗: Day 1
Cmax,0-6
tmax
时间窗: Day 1
tmax,0-6
AUC
时间窗: Day 1
AUC 0-6
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
A Study in Healthy Men to Test Whether Rifampicin Influences the Amount of BI 894416 in the BloodHealthyNCT04060719Boehringer Ingelheim16
已完成
1 期
The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected ParticipantsHIV-1-infectionTuberculosisNCT04424264Professor Francois Venter18
已完成
2 期
Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-DDiarrhea-predominant Irritable Bowel SyndromeNCT03099785Cosmo Technologies Ltd279
已完成
1 期
Effect of Rifampicin on the Pharmacokinetics of ApatinibNeoplasmsNCT02836821Jiangsu HengRui Medicine Co., Ltd.20
已完成
3 期
Study to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX) for the Treatment of Traveler's Diarrhea (TD)Traveler's DiarrheaNCT01142089Cosmo Technologies Ltd264